Macrophage LRRK2 hyperactivity impairs autophagy and induces Paneth cell dysfunction.

Area of Science:

• Gastroenterology
• Immunology
• Genetics

Background:

• LRRK2 (Leucine-rich repeat kinase 2) polymorphisms are linked to increased risk of Parkinson's disease and Crohn's disease (CD).
• Hyperactive LRRK2 kinase activity suppresses autophagy, a critical process for maintaining Paneth cell homeostasis.
• Paneth cell dysfunction is implicated in the gut inflammation characteristic of CD.

Purpose of the Study:

• To investigate the role of LRRK2 in Paneth cell dysfunction in CD.
• To explore LRRK2 kinase inhibition as a potential therapeutic strategy for CD.

Main Methods:

• Analysis of LRRK2 polymorphisms in CD patients and mouse models.
• Assessment of Paneth cell function and autophagy.
• Investigation of LRRK2 expression in intestinal cells.
• Evaluation of LRRK2 kinase inhibition effects on Paneth cell function and autophagy.

Main Results:

• CD patients and mice with hyperactive LRRK2 polymorphisms exhibited Paneth cell dysfunction.
• LRRK2 kinase was found to be expressed in lamina propria immune cells, not Paneth cells.
• LRRK2-mediated pro-inflammatory cytokine release impaired Paneth cell function.
• LRRK2 kinase inhibition restored autophagy and rescued Paneth cell function.

Conclusions:

• LRRK2 kinase hyperactivity contributes to Paneth cell dysfunction in CD.
• LRRK2 kinase inhibitors may represent a novel therapeutic approach for CD by restoring autophagy and Paneth cell homeostasis.